Study of anti-inflammatory activities of the pure compounds from Andrographis paniculata (burm.f.) Nees and their effects on gene expression

International Immunopharmacology

Volumn 10, Issue 11, 2010, Pages 1361-1373

  Parichatikanond, Warisara ^a   Suthisisang, Chuthamanee ^a   Dhepakson, Panadda ^b   Herunsalee, Angkana ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Andrographis paniculata; Andrographolide; Dehydroandrographolide; Gene expression; Inflammation; Neoandrographolide

Indexed keywords

11,12 DIDEHYDRO 14 DEOXYANDROGRAPHOLIDE; ANDROGRAPHOLIDE; CXCL11 CHEMOKINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DITERPENOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 3; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 2; NEOANDROGRAPHOLIDE; PROSTAGLANDIN SYNTHASE; STAT5A PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANDROGRAPHIS PANICULATA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA MICROARRAY; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADULT; ANDROGRAPHIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELETS; CALCIMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINES; DITERPENES; DOWN-REGULATION; GENE EXPRESSION; GLUCOSIDES; HUMANS; MALE; RECEPTORS, CYTOKINE; TETRAHYDRONAPHTHALENES; TOLL-LIKE RECEPTORS; YOUNG ADULT;

EID: 77958152946     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.08.002     Document Type: Article

References (53)

1. Farnsworth N., Bunyaprephatsara N. Thai medicinal plants 1992, Medicinal Plant Information Center, Faculty of Pharmacy, Mahidol University, Bangkok.
2. DerMarderosian A., Beutler J. The review of natural products: the most complete source of natural product information 2005, Facts & Comparisons, St. Louis, Mo. 4th ed.
3. Koteswara R.Y., Vimalamma G., Rao C.V., Tzeng Y.M. Flavonoids and andrographolides from Andrographis paniculata. Phytochemistry 2004, 65(16):2317-2321.
4. Reddy M.K., Reddy M.V., Gunasekar D., Murthy M.M., Caux C., Bodo B. A flavone and an unusual 23-carbon terpenoid from Andrographis paniculata. Phytochemistry 2003, 62(8):1271-1275.
5. Thamaree S., Rugrungtham K., Ruangrungsi N., Thaworn N., Kemsri W. The inhibitory effects of andrographolide and extracts of some herbal medicines on the production of proinflammatory cytokines by LPS-stimulated human blood cells. Chula Med J 2001, 45(8):661-670.
6. Panossian A., Davtyan T., Gukassyan N., Gukasova G., Mamikonyan G., Gabrielian E., et al. Effect of andrographolide and Kan Jang-fixed combination of extract SHA-10 and extract SHE-3-on proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture. Phytomedicine 2002, 9(7):598-605.
7. Wang T., Liu B., Zhang W., Wilson B., Hong J.S. Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J Pharmacol Exp Ther 2004, 308:975-983.
8. Chiou W.F., Lin J.J., Chen C.F. Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide. Br J Pharmacol 1998, 125(2):327-334.
9. Chiou W.F., Chen C.F., Lin J.J. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br J Pharmacol 2000, 129(8):1553-1560.
10. Shen Y.C., Chen C.F., Chiou W.F. Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol 2002, 135(2):399-406.
11. Shen Y.C., Chen C.F., Chiou W.F. Suppression of rat neutrophil reactive oxygen species production and adhesion by the diterpenoid lactone andrographolide. Planta Med 2000, 66(4):314-317.
12. Xia Y.F., Ye B.Q., Li Y.D., Wang J.G., He X.J., Lin X., et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004, 173(6):4207-4217.
13. Hidalgo M.A., Romero A., Figueroa J., Cortes P., Concha I.I., Hancke J.L., et al. Andrographolide interferes with binding of nuclear factor-kappa B to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol 2005, 144(5):680-686.
14. Chen J.H., Hsiao G., Lee A.R., Wu C.C., Yen M.H. Andrographolide suppresses endothelial cell apoptosis via activation of phosphatidyl inositol-3-kinase/Akt pathway. Biochem Pharmacol 2004, 67(7):1337-1345.
15. Tsai H., Yang L., Tsai W., Chiou W. Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. Eur J Pharmacol 2004, 498:45-52.
16. Qin L., Kong L., Shi G., Wang Z., GE B. Andrographolide inhibits the production of TNF-α and interleukin-12 in LPS-stimulated macrophages: role of mitogen-activated protein kinases. Biol Pharm Bull 2006, 29(2):220-224.
17. Dai G., Xu H., Wang J., Liu F., Liu H. Studies on the novel alpha-glucosidase inhibitory activity and structure-activity relationships for andrographolide analogues. Bioorg Med Chem Lett 2006, 16:2710-2713.
18. Pholphana N., Rangkadilok N., Thongnest S., Ruchirawat S., Ruchirawat M., Satayavivad J. Determination and variation of three active diterpenoids in Andrographis paniculata (Burm.f.) Nees. Phytochem Anal 2004, 15(6):365-371.
19. Hawiger J. Methods in enzymology: platelets: receptors, adhesion, secretion, part A 1989, Academic Press, Inc, New York.
20. Laufer S., Zechmeister P., Klein T. Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors. Inflamm Res 1999, 48(3):133-138.
21. Hermann C., von Aulock S., Graf K., Hartung T. A model of human whole blood lymphokine release for in vitro and ex vivo use. J Immunol Methods 2003, 275(1-2):69-79.
22. Knudsen S. Cancer diagnostics with DNA microarrays 2006, John Wiley & Sons, Inc, New Jersey.
23. Ashburner M., Ball C., Blake J.A., Botstein D., Butler H., Cherry M.J., et al. Gene Ontology: tool for the unification of biology. The Gene Ontology consortium. Nat Genet 2000, 25:25-29.
24. Dahlquist K., Salomonis N., Vranizan K., Lawlor S., Conklin B. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002, 31:19-20.
25. Kanehisa M., Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30.
26. Salomonis N., Hanspers K., Zambon A., Vranizan K., Lawlor S., Dahlquist K., et al. GenMAPP 2: new features and resources for pathway analysis. BMC Bioinform 2007, 8:217.
27. Khatri P., Voichita C., Kattan K., Ansari N., Khatri A., Georgescu C., et al. Onto-Tools: new additions and improvements in 2006. Nucleic Acids Res 2007, 35:W206-W211.
28. Rodenburg R.J., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF α, IL-1β, and IL-8 mRNA levels. A comparison of monocyte isolation procedures. J Immunol Meth 1998, 221:169-175.
29. Barth S., Kleinhappl B., Gutschi A., Jelovcan S., Marth E. In vitro cytokine mRNA expression in normal human peripheral blood mononuclear cells. Inflamm Res 2000, 49:266-274.
30. Kumar V., Abbas A.K., Fausto N., Mitchell R. Robbins basic pathology 2007, Elsevier Saunders, Philadelphia. 8th ed.
31. Botting R.M., Botting J.H. Pathogenesis and mechanisms of inflammation and pain: an overview. Clin Drug Invest 2000, 19:1-7.
32. Samad T.A., Sapirstein A., Woolf C.J. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002, 8:390-396.
33. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
34. Frolich J. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997, 18:30-34.
35. Sweeney F., Eskra J., Ernest M., Carty T. Spectrophotometric monitoring of lipoxygenase and cyclooxygenase pathway activity using ionophore stimulated whole blood. Inflamm Res 1987, 21:393-396.
36. von Aulock S., Hermann C., Hartung T. Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo. J Immunol Methods 2003, 277(1-2):53-63.
37. Thisoda P., Rangkadilok N., Pholphana N., Worasuttayangkurn L., Ruchirawat S., Satayavivad J. Inhibitory effect of Andrographis paniculata extract and its active diterpenoids on platelet aggregation. Eur J Pharmacol 2006, 553(1-3):39-45.
38. Poole S., Cunha F., Ferreira S. Hyperalgesia from subcutaneous cytokines. Cytokines and pain 1998, 59-87. Birkhäuser Verlag, Basel. L. Watkins, S. Maier (Eds.).
39. Hsu A., Ching T., Wang D., Song X., Rangnekar V., Chen C. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275:11397-11403.
40. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002, 531:278-284.
41. Elder D., Halton D., Playle L., Paraskeva C. The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002, 99:323-327.
42. Gerhold D., Jensen R., Gullans S. Better therapeutics through microarrays. Nat Genet 2002, 32:S547-S551.
43. Nadiminty N., Chun J., Hu Y., Dutt S., Lin X., Gao A. LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochem Biophys Res Commun 2007, 359(2):379-384.
44. Celik S., Langer H., Stellos K., May A.E., Shankar V., Kurz K., et al. Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium. Thromb Haemost 2007, 98(4):798-805.
45. Barnes P., Karin M. Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071.
46. Charo I., Ransohoff R. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
47. Zuany-Amorim C., Hastewell J., Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002, 1:797-807.
48. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7:179-190.
49. Schmitz F., Mages J., Heit A., Lang R., Wagner H. Transcriptional activation induced in macrophages by Toll-like receptor (TLR) ligands: from expression profiling to a model of TLR signaling. Eur J Immunol 2004, 34:2863-2873.
50. Kracht M., Saklatvala J. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 2002, 20:91-106.
51. Whitney A., Diehn M., Popper S., Alizadeh A., Boldrick J., Relman D., et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003, 100:1896-1901.
52. ® expression profiling. Santa Clara 2003, Available from: http://www.affymetrix.com/support/technical/technotes/blood_technote.pdf.
53. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6:79-87.